Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04062981 · ClinicalTrials.gov registry record · Phase 1

Carisbamate Safety Study in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome

A Phase 1 study of Lennox Gastaut Syndrome, sponsored by SK Life Science.

Completed
Registry status
Phase 1
Development phase
15
Enrollment target
5
Study locations

NCT04062981: Completed Phase 1 study of Lennox Gastaut Syndrome, sponsored by SK Life Science.

NCT04062981 is a Phase 1 study of Lennox Gastaut Syndrome that has completed, run by SK Life Science. The registered enrollment target is 15 participants, below the 606-participant average among 10 other Lennox Gastaut Syndrome trials with a reported enrollment target (98% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04062981, a Phase 1 study of Lennox Gastaut Syndrome, has completed, sponsored by SK Life Science.

COMPLETED
Registry status
Phase 1
Development phase
15 participants
Enrollment target
5
Study locations

Study Summary

Open-label extension study from YKP509C001 to evaluate the safety and tolerability of carisbamate in subjects with Lennox-Gastaut Syndrome (LGS).

Primary Outcome

Safety

Conditions Studied

Interventions

  • DRUG Carisbamate

Study Locations (5)

Maryland

  • Johns Hopkins Hospital - Baltimore

New Hampshire

  • Dartmouth-Hitchcock Medical Center - Lebanon

Oregon

  • Oregon Health and Science University - Portland

Utah

  • The University of Utah School of Medicine - Primary Children's Hospital (Primary Children's Medical Center) - Salt Lake City

Washington

  • UW Valley Medical Center - Renton

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2019-05-03
Est. Completion 2022-12-14
Phase Phase 1
SK Life Science

25 total trials

What the finished NCT04062981 record still lists

NCT04062981 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 606-participant average among 10 other Lennox Gastaut Syndrome trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Lennox Gastaut Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Carisbamate is the first listed.

NCT04062981 lists 5 locations in 5 states (Maryland, New Hampshire, Oregon).

Frequently Asked Questions

What is clinical trial NCT04062981 about?

NCT04062981 is a clinical study titled "Carisbamate Safety Study in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome". Open-label extension study from YKP509C001 to evaluate the safety and tolerability of carisbamate in subjects with Lennox-Gastaut Syndrome (LGS).

What is the current status of trial NCT04062981?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2019-05-03. Estimated completion is 2022-12-14.

What conditions does trial NCT04062981 study?

This clinical trial studies the following conditions: Lennox Gastaut Syndrome.

What interventions are being tested in trial NCT04062981?

The interventions under investigation include: Carisbamate (DRUG).

Who is sponsoring clinical trial NCT04062981?

This trial is sponsored by SK Life Science, which has 25 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04062981 being conducted?

This trial has 5 study locations across Maryland, New Hampshire, Oregon, Utah, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lennox Gastaut Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04062981's enrollment target sits among peer trials

15 10th of 10 higher than 1 of 10 other Lennox Gastaut Syndrome trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Lennox Gastaut Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01889381 · 15 participants · Phase 2

    Human Craniomaxillofacial Allotransplantation

  • NCT02530073 · 15 participants · NA

    Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH

  • NCT02535936 · 15 participants · NA

    Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy

  • NCT02918474 · 15 participants · NA

    Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04062981, the US trial registry maintained by the National Library of Medicine. NCT04062981 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.